Protohypericin
Based on 1 Customer Validation
Protohypericin is a compound that can be extracted from Hypericum perforatum. Protohypericin has low photocytotoxicity but can be efficiently photoconverted into Hypericin (HY-N0453) with high phototoxicity under visible light. Protohypericin can be used in cancer research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 95.0%
- CAS No.: 548-03-8
- Formule: C30H18O8
- Masse moléculaire:506.46
-
Stockage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Protohypericin (80-200 μM; 3-5 h) exhibits extremely low transepithelial transport rate and significant intracellular accumulation in Caco-2 cells[1].
Protohypericin (0.25-1 μM; 24 h incubation + 15 min irradiation) can induce photocytotoxicity in HeLa cells with a CC50 of 0.21 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 548-03-8
-
Appearance Solid
-
Masse moléculaire 506.46
-
Formule C30H18O8
-
Color Purple to black
-
SMILES
O=C(C1=C(O)C=C(C)C=C1C2=C34)C3=C(O)C=C(O)C4=C5C(O)=CC(O)=C6C(C7=C(O)C=C(C)C=C7C2=C65)=O
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvant et solubilité
DMSO : 25 mg/mL (49.36 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.94 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (284 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Kamuhabwa AR, et al. In vitro transport and uptake of protohypericin and hypericin in the Caco-2 model. Int J Pharm. 1999 Oct 15;188(1):81-6. [Content Brief]
[2]. Delaey EM, et al. Photocytotoxicity of protohypericin after photoconversion to hypericin. Planta Med. 1999 Dec;65(8):719-22. [Content Brief]
[3]. Liu X, et al. Tumor necrosis targeted radiotherapy of non-small cell lung cancer using radioiodinated protohypericin in a mouse model. Oncotarget. 2015 Sep 22;6(28):26400-10. [Content Brief]
[4]. Baugh SF. Simultaneous determination of protopseudohypericin, pseudohypericin, protohypericin, and hypericin without light exposure. J AOAC Int. 2005 Nov-Dec;88(6):1607-12. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9745 mL | 9.8724 mL | 19.7449 mL | 49.3622 mL |
| 5 mM | 0.3949 mL | 1.9745 mL | 3.9490 mL | 9.8724 mL | |
| 10 mM | 0.1974 mL | 0.9872 mL | 1.9745 mL | 4.9362 mL | |
| 15 mM | 0.1316 mL | 0.6582 mL | 1.3163 mL | 3.2908 mL | |
| 20 mM | 0.0987 mL | 0.4936 mL | 0.9872 mL | 2.4681 mL | |
| 25 mM | 0.0790 mL | 0.3949 mL | 0.7898 mL | 1.9745 mL | |
| 30 mM | 0.0658 mL | 0.3291 mL | 0.6582 mL | 1.6454 mL | |
| 40 mM | 0.0494 mL | 0.2468 mL | 0.4936 mL | 1.2341 mL |
Protohypericin Related Classifications
HY-N4139 Related Classifications
Powered by Bioz